Hadron therapy: advantage over traditional radiation therapy methods and its specificity for Georgia
Keywords:
Proton therapy, Hadron therapy, Radiation therapy, Pediatric oncology, Cancer, Secondary tumor, Proton scalpel, Pencil beamAbstract
Proton therapy is the impact of the flow of accelerated ionizing particles, in this case accelerated protons, on the irradiated tissue. Due to the relatively large mass, the proton flow is only slightly scattered across the tissues, the beam can be directed directly to the tumor without damaging the surrounding healthy tissues. Practically the entire radiation dose is released in the tumor tissue and does not damage the surrounding healthy tissues. This is especially important in the treatment of children, when long-term irradiation with excessive radiation doses contributes to the occurrence of secondary tumors. Proton therapy is indispensable in the treatment of tumors surrounding vital organs, such as the skull, optic nerve, and intestine. Another advantage of hadron therapy compared to radiation therapy is its high efficiency. Treatment efficiency is 80-90%, the whole course consists of 1-10 sessions. For comparison, 30-40 sessions of radiation therapy are needed to achieve a similar effect.
References
Bradley, JD., Paulus, R., Komaki, R., et al. 2011. “A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy +/? cetuximab for stage IIIA/IIIB nonsmall cell lung cancer: preliminary findings on radiation dose in RTOG 0617” [abstract] // Miami Beach, FL: 53rd Annual Meeting of the American Society for Radiation Oncology.
Curran, WJJr., Paulus, R., Langer, CJ., et al. 2011. “Sequential vs. concur-rent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410” // J Natl Cancer Inst. Vol. 103 (19). 2011:1452–1460.
Cox, JD., 2012. “Are the results of RTOG 0617 mysterious?” // Int J Radiat Oncol Biol Phys. Vol. 82(3). 2012: 1042–1044.
Coen, JJ., Bae, K., Zietman, AL., et al. 2011. “Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12” // Int J Radiat Oncol Biol Phys. Vol. 81. 2011: 1005–1009.
Chung, C.S., et al. 2013. “Incidence of second malignancies among patients treated with proton versus photon radiation” // Int. J. Radiat. Oncol. Biol. Phys. Vol. 87. 2013: 46–52.
Fukumitsu, N., Okumura, T., Mizumoto, M., et al. 2012. “Outcome of T4 (International Union Against Cancer Staging System, 7th edition) or re-current nasal cavity and paranasal sinus carcinoma treated with proton beam // Int J Radiat Oncol Biol Phys. Vol. 83. 2012: 704-711.
King, CR., Brooks, JD., Gill, H., Presti, JC Jr. 2012. “Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer” // Int J Radiat Oncol Biol Phys. Vol. 82(2). 2012: 877–882.
McDonald, MW., Linton, OR., Shah, MV. 2013. “Proton therapy for reirra-diation of progressive or recurrent chordoma” // Int J Radiat Oncol Biol Phys. Vol. 87. 2013:1107-1114.
Okano, S., Tahara, M., Zenda, S., et al. 2012. “Induction chemotherapy with docetaxel, cisplatin and S-1 followed by proton beam therapy concurrent with cisplatin in patients with T4b nasal and sinonasal malignancies” // Jpn J Clin Oncol. Vol. 42. 2012:691-696.
Resto, VA., Chan, AW., Deschler, DG., et al. 2008. “Extent of surgery in the management of locally advanced sinonasal malignancies” // Head Neck. Vol. 30. 2008: 222-229.
Rombi, B., Ares, C.,, Hug EB., et al. 2013. “Spot-scanning proton radiation therapy for pediatric chordoma and chondrosarcoma: Clinical outcome of 26 patients treated at Paul Scherrer Institute” // Int J Radiat Oncol. Vol. 86. 2013: 578-584.
Sejpal, S., Komaki, R., Tsao, A., et al. 2011. “Early Findings on Toxicity of Proton Beam Therapy with Concurrent Chemotherapy in Nonsmall Cell Lung Cancer” // Cancer. Vol. 117. 2011: 3004–3013.
Truong, MT., Kamat, UR., Liebsch, NJ., et al. 2009. “Proton radiation thera-py for primary sphenoid sinus malignancies: Treatment outcome and prognostic factors” // Head Neck. Vol. 31. 2009: 1297-1308.
Van de Water, TA., Lomax, AJ., Bijl, HP., et al. 2011. “Potential benefits of scanned intensity-modulated proton therapy versus advanced photon therapy with regard to sparing of the salivary glands in oropharyngeal cancer” // Int J Radiat Oncol Biol Phys. Vol. 79. 2011: 1216-1224.
Van de Water, TA., Lomax, AJ., Bijl, HP., et al. 2012. “Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer” // Int J Radiat Oncol Biol Phys. Vol. 82. 2012: e313-e319.
Van der Laan, HP., van de Water, TA., van Herpt, HE., et al. 2013. “The potential of intensity-modulated proton radiotherapy to reduce swallow-ing dysfunction in the treatment of head and neck cancer: A planning comparative study” // Acta Oncol. Vol. 52. 2013: 561-569.
Van de Water, TA., Lomax, AJ., Bijl, HP., et al. 2011. “Potential benefits of scanned intensity-modulated proton therapy versus advanced photon therapy with regard to sparing of the salivary glands in oropharyngeal cancer” // Int J Radiat Oncol Biol Phys. Vol. 79. 2011: 1216-1224.
Zenda, S., Kohno, R., Kawashima, M., et al. 2011. “Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses” // Int J Radiat Oncol Biol Phys. Vol. 81. 2011: 1473-1478.
Zhang, R., et al. 2014. “A comparative study on the risks of radiogenic sec-ond cancers and cardiac mortality in a set of pediatric medulloblastoma patients treated with photon or proton craniospinal irradiation” // Radi-other. Oncol. Vol. 113. 2014: 84–88.
